Sharps Technology Reports Strong Q3 Growth and Completes Exit from Syringe Manufacturing

Sharps Technology Inc. reported financial results for the third quarter ended September 30, 2025, highlighting a strategic transformation of its business. The company raised $411 million in gross proceeds through a PIPE financing, funded with $267 million in cash and stablecoins and $144 million in SOL. As of October 31, 2025, the company holds over 2.0 million SOL in its treasury. Sharps Technology generated approximately $17.7 million in combined staking revenue and digital-asset fair-value gains during the third quarter. Cash and stablecoin liquidity stood at approximately $25.2 million as of September 30, 2025. During the quarter, 315,805 Series A warrants were exercised for net proceeds of $1.9 million, and 388,462 pre-funded warrants were exercised for nominal cash consideration. The company also completed its planned exit from legacy syringe manufacturing, streamlining operations and reducing ongoing costs. Sharps Technology is now focused on the sale and distribution of medical device products with an emphasis on higher margins and operational efficiency, alongside maximizing value from its Solana-based digital asset treasury. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sharps Technology Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here